BOEHRINGER-INGELHEIM
20.9.2019 14:02:07 CEST | Business Wire | Press release
Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies for patients with retinal diseases. By combining Inflammasome’s unique intravitreal (IVT) drug delivery technologies with Boehringer Ingelheim’s compounds from its retinal disease pipeline portfolio, Boehringer Ingelheim aims to develop novel therapies for retinal diseases.
In 2019 there were an estimated 82 million patients in the seven key countries (U.S., Japan, Germany, U.K., Spain, Italy, France) affected by one of the three major forms of retinal disease: Age related macular degeneration (AMD), diabetic retinopathy (DR), and diabetic macular edema (DME). Globally, the prevalence rates of these and other retinal diseases are expected to increase over the next 10 years primarily due to aging populations and the global diabetes epidemic. Despite therapeutic advances in some disease areas during the past years, the real world results are poor, and there are no or only limited treatment options in many areas, resulting in an overall high unmet need. The collaboration between Boehringer Ingelheim and Inflammasome aims to address this challenge by using Inflammasome’s technology to deliver therapeutics in a biodegradable gel formulation into the eye.
“We are delighted to enter into a collaboration with a company of Boehringer Ingelheim’s stature,” said Paul Ashton, Chief Executive Officer of Inflammasome Therapeutics. “We look forward to working with their team to leverage our respective technologies and expertise to develop new therapies for devastating retinal diseases leading to blindness. This collaboration fits our strategy of advancing the company via both collaborations and internal development.”
“Boehringer Ingelheim is looking forward to developing Inflammasome’s novel technology for the delivery of our first-in- class retinal disease compounds working jointly with Inflammasome’s highly experienced scientific team,” said Clive R. Wood, PhD, Senior Corporate Vice President, Discovery Research at Boehringer Ingelheim. “This will enable us to develop a broad range of novel therapy options for the many patients with retinal diseases waiting urgently for better and new therapy options.”
Boehringer Ingelheim takes a holistic approach in the development of novel retinal disease therapies, targeting key mechanisms in the pathogenesis of retinal diseases. The company has built a comprehensive pipeline portfolio of next generation therapy approaches in various stages of development up to Phase 2 in macular degeneration, diabetic retinal diseases and beyond. Inflammasome’s novel delivery technology using a long-acting degradable IVT implant complements this portfolio.
Inflammasome is entitled to receive up to $160 million in up-front, research and development support and milestone gated development payments as well as tiered royalties based on future commercial sales of developed products and other milestones due on commercialization.
Please click on the link for ´Notes to Editors´and ´References´:
http://www.boehringer-ingelheim.com/press-release/collaboration-novel-therapies-retinal-diseases
View source version on businesswire.com: https://www.businesswire.com/news/home/20190920005149/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ATLAS Infrastructure Cornerstones United Utilities £800m Equity Placement5.5.2026 13:12:00 CEST | Press release
ATLAS participated as an exclusive Cornerstone investor in United Utilities’ equity placement, expanding its existing investment to establish a significant minority shareholding.ATLAS was pleased with the strong support for the transaction from other long-term shareholders signalling broad support for United Utilities’ investment and growth strategy.United Utilities’ fully funded capital investment program underpins a strong multi-year growth trajectory1. ATLAS Infrastructure (“ATLAS”) is a specialist Global Listed Infrastructure investor managing capital on behalf of its funds and long-term institutional clients. ATLAS has been an investor in UU since 2019 and, following the recent equity placement, ATLAS’s actively managed accounts hold a ~6.6% voting and economic interest in United Utilities plc (“UU”). ATLAS recognises the positive new direction established for the UK water sector and welcomes the opportunity to support UU management’s investment plan which will deliver the critica
Jeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent5.5.2026 12:37:00 CEST | Press release
Highly experienced partners bringing 25+ years of leadership across top-tier life-sciences investment fund, pharma and Biopharma companies, driving accelerated portfolio developmentWith leadership experienceat Blackstone Life Sciences (Deputy Chief Operating Officer), Biogen, (NASDAQ: BIIB), and public and private Biopharma companies (including Kymera Therapeutics (NASDAQ: KYMR)and Cygnal Therapeutics), Elaine Caughey will support portfolio companies in strengthening operational execution, defining robust market access pathways, and enhancing their strategic value through business development support, including partnerships and acquisition transactions. She will also draw on her knowledge of the investment ecosystem to strengthen relationships with investors for both Jeito funds and its portfolio companiesSarah brings deep strategic expertise from senior roles at leading Biopharma investment firms - including as Partner, Marketing and Talent at Abingworth and as Chief Talent Officer at
Datang Mobile, KPN, NEC and Wilus are Latest Licensors to Join Sisvel POS Patent Pool as Incentive Deadline Nears5.5.2026 10:02:00 CEST | Press release
Datang Mobile, KPN, NEC and Wilus have become the latest licensors in the Sisvel point of sale (POS) patent pool. They join seven other patent owners in making their 2G-5G cellular portfolios available through the programme: BlackBerry, Huawei, JVCKENWOOD, LG Electronics, Nokia, Sisvel and SK Telecom. The period for Sisvel POS licensors to benefit from early participation incentives is set to close on 15 May. Cellular patent owners interested in becoming involved should contact Sisvel as soon as possible. The pool, which is the first in the market to address the POS vertical, was announced at the beginning of April, with Huawei, LG Electronics and Nokia as founding licensors. “We have received a great response from the market so far, and I am pleased to welcome Datang, KPN, NEC and Wilus as the latest licensors,” says POS programme manager Sven Törringer. “We have put together a formidable group of cellular technology innovators, and there are many more companies in the pipeline. I am
Bregal Milestone Announces Majority Growth Investment in meteoviva, an AI-Powered Building Energy Management Solution5.5.2026 10:01:00 CEST | Press release
Partnership to scale one of Europe's largest autonomous energy management solutions amid accelerating decarbonisation mandates and rising AI adoption in commercial real estate Bregal Milestone, a leading European software growth private equity firm, today announced a majority growth investment in meteoviva GmbH (“meteoviva” or the “Company”), a pioneer in AI-powered predictive building energy management. meteoviva's intelligent solutions combine a proprietary physics-based thermodynamic model with AI to deliver energy cost reductions of up to 45 percent across large-scale commercial real estate portfolios, without structural retrofits. meteoviva is widely recognised as a market leader in autonomous building energy management, with over 500 buildings across 19 countries, accounting for 11.5 million square metres of real estate under active control. Its customer base includes some of Europe's most demanding buildings, among them Germany's largest office building, The Squaire at Frankfurt
Schindler Selects Navan to Elevate Global Travel Operations5.5.2026 10:00:00 CEST | Press release
Leading provider of sustainable and smart urban mobility deploys Navan to deliver a seamless experience for its workforce Navan (NASDAQ: NAVN), the global AI-powered business travel and expense management platform, today announced it has been selected by Schindler, the leading provider of sustainable and smart urban mobility, to modernize its global travel program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505725595/en/ Leading provider of sustainable and smart urban mobility deploys Navan to deliver a seamless experience for its workforce With over 150 years of industry innovation, Schindler has reshaped mobility in urban societies, growing from a local manufacturer into a global elevator, escalators and moving walkways business. To support its next phase of growth, the company has chosen to consolidate its travel operations – moving away from a fragmented online booking model. By deploying Navan, Schindler is now u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom